Molecular Cancer最新文献_第2页

Breast cancer immunotherapy: mechanisms of immune evasion, biomarkers, and emerging therapeutic strategies. 乳腺癌免疫治疗：免疫逃避机制、生物标志物和新兴治疗策略。

IF 37.3 1区医学

Molecular Cancer Pub Date : 2026-04-25 DOI: 10.1186/s12943-026-02655-0

Valentin P Shichkin,Ahsen Morva,Vijay K Ulaganathan,Nuray Erin,Cristina Nativi,Simona Kranjc Brezar,Sweta Rani

引用次数: 0

The RNA methylation modification as an immunometabolic regulatory hub in pancreatic cancer: from mechanistic insights to clinical translation perspectives. RNA甲基化修饰作为胰腺癌的免疫代谢调节中心：从机制的见解到临床翻译的观点。

IF 37.3 1区医学

Molecular Cancer Pub Date : 2026-04-22 DOI: 10.1186/s12943-026-02667-w

Yinghao Zhu,Kai Ma,Qisheng Hao,Kang Fu,Faxian Hei,Ning Sun,Zhiguo Yin,Weidong Guo,Hao Zou,Zhen Tan

引用次数: 0

Genetically driven immune microenvironment states associate with therapeutic responses in MYD88 mutant lymphomas. 基因驱动的免疫微环境状态与MYD88突变型淋巴瘤的治疗反应相关。

IF 37.3 1区医学

Molecular Cancer Pub Date : 2026-04-20 DOI: 10.1186/s12943-026-02646-1

Jon Celay,Miriam Recalde,Maria V Revuelta,Marta Larrayoz,Carmen Vicente,Teresa Lozano,Carmen Gil,Jennifer R Chapman,Marcos Garcia-Lacarte,Carmen Gonzalez,Beñat Ariceta,Sara Rodriguez,Marta Lasa,Maria J Garcia-Barchino,Vicente Fresquet,Maddalen Jimenez,Sonia Sanz,Ming-Qing Du,Giovanna Roncador,Zaira Vega,Antonio Sacco,Aldo Roccaro,Gero Knittel,Hans Christian Reinhardt,Rocco Piazza,Sylvia Herter,Rebecca Goodhew,Jonathan Caron,Damien Roos-Weil,Jesus San Miguel,Miguel Canales,Daniel J Hodson,Izidore S Lossos,Juan J Lasarte,Sergio Roa,Felipe Prosper,Bruno Paiva,Leandro Cerchietti,Jose A Martinez-Climent

引用次数: 0

MTSS1-dependent ubiquitin modifications mediated by FBXO44 remodel the actin cytoskeleton to promote gastric cancer progression. FBXO44介导的mtss1依赖性泛素修饰重塑肌动蛋白细胞骨架，促进胃癌进展。

IF 37.3 1区医学

Molecular Cancer Pub Date : 2026-04-17 DOI: 10.1186/s12943-026-02668-9

Guangzhao Pan,Qianqian Xu,Li Yuan,Lingling Wang,Che Zhang,Jiahan Le,Jing Zhao,Kui Zhang,Xin Hu,Hui Liang,Xiangliu Chen,Jinyun Dong,Xiaoqing Guan,Fangfang Tao,Kai Miao,Zhe-Sheng Chen,Jiang-Jiang Qin

引用次数: 0

Retraction Note: Epigenetic modification of ferroptosis by non-coding RNAs in cancer drug resistance. 注：非编码rna修饰铁下垂在癌症耐药中的表观遗传修饰。

IF 33.9 1区医学

Molecular Cancer Pub Date : 2026-04-16 DOI: 10.1186/s12943-026-02662-1

Hongquan Wang, Joshua S Fleishman, Sihang Cheng, Weixue Wang, Fan Wu, Yumin Wang, Yu Wang

引用次数: 0

The evolving role of OMICS in gastrointestinal tumor biology and clinical practice. 组学在胃肠道肿瘤生物学和临床实践中的发展作用。

IF 37.3 1区医学

Molecular Cancer Pub Date : 2026-04-16 DOI: 10.1186/s12943-026-02658-x

Qing Li,Junfeng Zhang,Junli Chen,Qiang Zhang,Ruihan Liu,Jialin Zhu,Yi Qing,Xi Wei,Jianpeng Sheng

{"title":"The evolving role of OMICS in gastrointestinal tumor biology and clinical practice.","authors":"Qing Li,Junfeng Zhang,Junli Chen,Qiang Zhang,Ruihan Liu,Jialin Zhu,Yi Qing,Xi Wei,Jianpeng Sheng","doi":"10.1186/s12943-026-02658-x","DOIUrl":"https://doi.org/10.1186/s12943-026-02658-x","url":null,"abstract":"Due to late diagnosis, high molecular diversity, and limited response to therapeutic intervention, gastrointestinal (GI) cancers result in a considerable number of cancer-related deaths. Classic clinicopathological classification and single omics analysis fail to adequately convey the extensive biological complexity related to progression of disease, developed therapy resistance and recurrence of the disease. As a result, the recent introduction of integrated multi-omics including genomics, epigenomics, transcriptomics, proteomics, metabolomics and spatial profiling as well as the emerging use of liquid biopsy is substantially reshaping our understanding of and clinical approach to GI cancers. This review summarizes developments to illustrate how the incorporation of multi-omics across GI tumors offers a better understanding of GI cancers and providing more precise and less costly ways to detect disease earlier, develop molecular subtypes of the tumors with greater accuracy for the purpose of developing an individualized risk stratification system for patients. Furthermore, the article will discuss the growing use of minimal residual disease monitoring and the use of ctDNA in guiding a patient's post-operative surveillance and treatment decision-making process. In addition, this review focuses on the value of using multi-omics-based knowledge of a tumor's microenvironment to better predict how effective immunotherapy will be and support the effective combination of drugs for the treatment of GI cancers and how targeted therapy will broaden the clinical practice landscape for developing therapeutics containing new vulnerable targets. Finally, the review provides an overview of current barriers to the implementation of multi-omics and point out to future opportunities. Collectively, emerging omics data suggest a meaningful shift toward precision oncology in gastrointestinal cancers, though widespread clinical implementation remains an active area of investigation.","PeriodicalId":19000,"journal":{"name":"Molecular Cancer","volume":"13 1","pages":""},"PeriodicalIF":37.3,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147695060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

CDK6/4 inactivates BAP1 deubiquitinase destabilizing VHL to promote metastatic colonization in liver. CDK6/4灭活破坏VHL稳定的BAP1去泛素酶，促进肝脏转移定定。

IF 37.3 1区医学

Molecular Cancer Pub Date : 2026-04-15 DOI: 10.1186/s12943-026-02650-5

Bei Jin,Luo Yang,Weijia Peng,Zhongwen Luo,Dong Wei,Jing Zhang,Li Zhao,Jinqiu Zhong,Qianyun Ye,Peirong Li,Ping Zhang,Li Liang,Jingxuan Pan

引用次数: 0

Immunogenic cell death as a cornerstone for combination therapies with immune checkpoint blockade. 免疫原性细胞死亡是免疫检查点阻断联合治疗的基石。

IF 37.3 1区医学

Molecular Cancer Pub Date : 2026-04-14 DOI: 10.1186/s12943-026-02663-0

Yubo Niu,Shuangli Zhu,Kai Fu,Yongtong Lai,Can Pan,Yan Yang,Sijia Li,Xueping Wang,Kenneth Kin Wah To,Fang Wang,Liwu Fu

引用次数: 0

Smart hydrogels for overcoming cancer multidrug resistance. 克服癌症多药耐药的智能水凝胶。

IF 37.3 1区医学

Molecular Cancer Pub Date : 2026-04-11 DOI: 10.1186/s12943-026-02660-3

Yong Wang,Baoyan Liu,Zou-Fang Huang,Harsh Patel,Jinming Yu,Man Hu,Zhe-Sheng Chen

{"title":"Smart hydrogels for overcoming cancer multidrug resistance.","authors":"Yong Wang,Baoyan Liu,Zou-Fang Huang,Harsh Patel,Jinming Yu,Man Hu,Zhe-Sheng Chen","doi":"10.1186/s12943-026-02660-3","DOIUrl":"https://doi.org/10.1186/s12943-026-02660-3","url":null,"abstract":"Multidrug resistance (MDR) remains the principal impediment to curative oncology, driven by complex interplays between cancer cells and the tumor microenvironment (TME). While nanomedicines have sought to overcome these delivery barriers, their clinical translation is often hampered by the heterogeneity of the enhanced permeability and retention (EPR) effect and by inefficient intratumoral delivery. In this review, we argue that overcoming MDR requires a transition beyond traditional passive drug delivery, advocating active, localized remodeling of the tumor ecosystem. Next-generation injectable hydrogels are increasingly recognized as localized viscoelastic niches that combine controlled intratumoral retention with the capacity to actively modulate biological responses within tumor TME. By converging principles of mechanobiology and immunometabolism, these hydrogels enable a multi-tiered strategy to dismantle multidimensional MDR. This approach begins with the biomechanical softening of the extracellular matrix to decouple mechanotransduction driven by Yes-associated protein (YAP) and transcriptional coactivator with PDZ-binding motif (TAZ), followed by the metabolic disruption of hypoxia-driven bioenergetics. Beyond the extracellular landscape, nanogel-enabled trafficking allows payloads to circumvent intracellular sequestration and efflux transporters, while immunomodulatory niches mobilize antitumor immunity through in situ vaccination and myeloid reprogramming. Finally, we evaluate the integration of artificial intelligence-driven design and patient-derived organoids as a technical bridge to reconcile laboratory ingenuity with clinical utility, aiming to transform the TME into a vulnerable therapeutic target.","PeriodicalId":19000,"journal":{"name":"Molecular Cancer","volume":"18 1","pages":""},"PeriodicalIF":37.3,"publicationDate":"2026-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147648863","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

KRAS and MYC synergistic inhibition: a powerful strategy targeting KRAS-mutant cancers. KRAS和MYC协同抑制：一种针对KRAS突变癌症的强大策略。

IF 37.3 1区医学

Molecular Cancer Pub Date : 2026-04-10 DOI: 10.1186/s12943-026-02659-w

Man Yan,Kai Liu,Jing Xu,Yandi Liu,Liechen Ji,Shiwu Zhang

引用次数: 0